These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2531559)

  • 1. Adverse responses following intraoperative administration of orthoclone OKT3.
    Roth S; Kupferberg JP
    Anesth Analg; 1989 Dec; 69(6):822-5. PubMed ID: 2531559
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients.
    Bloemena E; ten Berge IJ; Surachno J; Wilmink JM
    Transplantation; 1990 Aug; 50(2):330-1. PubMed ID: 2143327
    [No Abstract]   [Full Text] [Related]  

  • 4. Fine-needle aspiration cytology during treatment with orthoclone monoclonal antibody OKT3 for acute cellular rejection after renal transplantation.
    Hansen BL; Foged N; Nielsen E; Elbirk A; Rohr N; Svendsen V; Birkeland SA
    Transplant Proc; 1988 Aug; 20(4):626-8. PubMed ID: 2970142
    [No Abstract]   [Full Text] [Related]  

  • 5. Reactivity of patient antisera to OKT3 with a panel of CD3 monoclonal antibodies.
    Nashan B; Schwinzer R; Wonigeit K; Pichlmayr R
    Transplant Proc; 1989 Feb; 21(1 Pt 1):985-6. PubMed ID: 2523157
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting.
    Burke GW; Vercellotti GM; Simmons RL; Howe RB; Canafax DM; Najarian JS
    Transplantation; 1989 Sep; 48(3):403-8. PubMed ID: 2528849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are OKT3 binding sites on T cells modulated or merely converted (blindfolded) by OKT3 during therapy?
    Carreno M; Miller J; Esquenazi V; Milgrom M; Roth D; Fuller L
    Transplant Proc; 1989 Feb; 21(1 Pt 1):987-8. PubMed ID: 2565060
    [No Abstract]   [Full Text] [Related]  

  • 8. An overview of the use of the monoclonal antibody OKT3 in renal transplantation.
    Norman DJ
    Transplant Proc; 1988 Dec; 20(6):1248-52. PubMed ID: 2974204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation.
    Frenken LA; Hoitsma AJ; Tax WJ; Koene RA
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1072-3. PubMed ID: 1824887
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute cellular rejection during effective early prophylactic OKT3 monoclonal antibody treatment after renal transplantation.
    Haak HH; Weening JJ; Rischen-Vos J; Daha MR; van Es LA; van der Woude FJ
    Transplantation; 1989 Aug; 48(2):352-4. PubMed ID: 2526973
    [No Abstract]   [Full Text] [Related]  

  • 11. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.
    Li PK; Nicholls MG; Lai KN
    Adverse Drug React Acute Poisoning Rev; 1990; 9(3):123-55. PubMed ID: 1703724
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions.
    Alegre M; Depierreux M; Florquin S; Najdovski T; Vandenabeele P; Abramowicz D; Leo O; Deschodt-Lanckman M; Goldman M
    Transplant Proc; 1990 Aug; 22(4):1920-1. PubMed ID: 2143864
    [No Abstract]   [Full Text] [Related]  

  • 13. [Nephrotoxicity of anti-CD3 monoclonal antibodies].
    Alegre ML; Depierreux M; Florquin S; Abramowicz D; De Pauw L; Kinnaert P; Vereerstraeten P; Goldman M
    Nephrologie; 1991; 12(1):42-5. PubMed ID: 1827878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 resistant rejection in liver transplant patients.
    Sutherland F; Lazarovits A; Aboujaoude M; Grant D; Ghent C; Sommerauer J; Wall W
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1413-4. PubMed ID: 1824898
    [No Abstract]   [Full Text] [Related]  

  • 15. Discordant expression of CD3 and T-cell receptor antigens on lymphocytes from patients treated with OKT3.
    Gebel HM; Lebeck LL; Jensik SC; Landay AL; Bray RA
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1745-6. PubMed ID: 2523590
    [No Abstract]   [Full Text] [Related]  

  • 16. The human antimouse reaction to OKT3: cross-reactive pattern analysis using a large group of anti-CD3 and isotypic monoclonal antibodies.
    Shield CF; Hughes JD; Marlett P; Norman DJ
    Transplant Proc; 1989 Feb; 21(1 Pt 1):981-4. PubMed ID: 2523156
    [No Abstract]   [Full Text] [Related]  

  • 17. Human T cell activation: participation of Tll antigen (CD2, T,gp.50) in T cell-accessory cell interactions.
    Suthanthiran M
    Transplant Proc; 1987 Feb; 19(1 Pt 1):336-7. PubMed ID: 2908550
    [No Abstract]   [Full Text] [Related]  

  • 18. [The immunobiology of transplant rejection and its pharmacological modification].
    Köhler H; Zanker B; Strom TB
    Dtsch Med Wochenschr; 1991 Feb; 116(7):264-9. PubMed ID: 1825196
    [No Abstract]   [Full Text] [Related]  

  • 19. RIV-9: a mouse IgG3 anti-human CD3 monoclonal antibody with strong antigen modulating and T cell eliminating properties.
    Vaessen LM; Kreeftenberg JG; Heyse P; Leerling MF; Baumgartner D; Hendriks GF; Jutte NH; Weimer W
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1026-7. PubMed ID: 2523112
    [No Abstract]   [Full Text] [Related]  

  • 20. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.